Full Text Full Text (PDF) Email this article to a Colleague Similar articles in this journal Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via Google Scholar Articles by Mrazek, D. A. Search for Related Content Articles by Mrazek, D. A.

Psychiatric Pharmacogenomics

Correspondence: Address correspondence to David A. Mrazek, M.D., F.R.C.Psych., Department of Psychiatry and Psychology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.

The field of psychiatric genomics has developed dramatically over the past 10 years. The essential goal of psychiatric pharmacogenomics is to measure genetic variation in individual patients to predict their response to psychotropic medications. The initial application of pharmacogenetic testing has been to identify patients who have structural and functional changes in their drug-metabolizing enzyme genes that are associated with increased serum levels of medication at standard doses. More recently, genetic variance in the serotonin transporter gene and the serotonin 2A receptor gene has been used to predict the response of patients to selective serotonin reuptake inhibitors.

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us